Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

International Agency for Research on Cancer, World Health Organization. https://gco.iarc.fr. Accessed 28 Nov 2023.

Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–73.

Article  PubMed  Google Scholar 

Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555–67.

Article  PubMed  Google Scholar 

Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50(1):12–20.

Article  PubMed  Google Scholar 

Shirakawa T, Kato K, Nagashima K, et al. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemother Pharmacol. 2014;74(6):1207–15.

Article  CAS  PubMed  Google Scholar 

Shim HJ, Cho SH, Hwang JE, et al. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Am J Clin Oncol. 2010;33(6):624–8.

Article  CAS  PubMed  Google Scholar 

Oh S, Kim E, Lee H. Comparative impact of PD-1 and PD-L1 inhibitors on advanced esophageal or gastric/gastroesophageal junction cancer treatment: a systematic review and meta-analysis. J Clin Med. 2021;10(16):3612.

Article  PubMed  PubMed Central  Google Scholar 

Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–17.

Article  CAS  PubMed  Google Scholar 

Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–48.

Article  CAS  PubMed  Google Scholar 

Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832–42.

Article  CAS  PubMed  Google Scholar 

Shen L, Kato K, Kim SB, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40(26):3065–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chinese Society of Clinical Oncology Guideline Committee. Clinical Practice Guidelines for Esophageal Cancer by the Chinese Society of Clinical Oncology (CSCO). Beijing: People’s Medical Publishing House. 2022;68-91. ISBN: 9787117329637

Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.

Article  PubMed  PubMed Central  Google Scholar 

Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.

Article  PubMed  PubMed Central  Google Scholar 

Jansen JP. Network meta-analysis of survival data with fractional polynomials. BMC Med Res Methodol. 2011;11:61.

Article  PubMed  PubMed Central  Google Scholar 

Petersohn S, McGregor B, Klijn SL, et al. Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma. J Comp Eff Res. 2023;12(8):e230004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS ONE. 2012;7(3):e32530.

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Bureau of Statistics of the People's Republic of China. https://data.stats.gov.cn/easyquery.htm?cn=A01&zb=A010101&sj. Accessed 25 Nov 2023.

Zhang PF, Xie D, Li Q. Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma. Future Oncol. 2020;16(17):1189–98.

Article  CAS  PubMed  Google Scholar 

Liu G, Hu S, Wu J, et al. China guidelines for pharmacoeconomic evaluations. Beijing: China Market Press; 2020. p. 27–8.

Google Scholar 

Okada M, Kato K, Cho BC, et al. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res. 2022;28(15):3277–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Information of Drug Winning Bid. https://db.yaozh.com. Accessed 25 Nov 2023.

Zhang Q, Wu P, He X, et al. Cost-effectiveness analysis of camrelizumab vs. placebo added to chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China. Front Oncol. 2021;11:790373.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li L, Liu X, Huang J, et al. Cost-effectiveness of camrelizumab versus chemotherapy for the treatment of advanced or metastatic esophageal squamous cell carcinoma. J Gastrointest Oncol. 2022;13(1):40–8.

Article  PubMed  PubMed Central  Google Scholar 

Gong J, Su D, Shang J, et al. Cost-effectiveness of tislelizumab versus docetaxel for previously treated advanced non-small-cell lung cancer in China. Front Pharmacol. 2022;13:830380.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195–203.

Article  PubMed  Google Scholar 

Zargar M, McFarlane T, Chan KKW, et al. Cost-effectiveness of nivolumab in recurrent metastatic head and neck squamous cell carcinoma. Oncologist. 2018;23(2):225–33.

Article  CAS  PubMed  Google Scholar 

Liu S, Dou L, Wang K, et al. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma. Front Oncol. 2022;12:899966.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie Q, Luo Y, Peng X. Cost-effectiveness analysis of pembrolizumab for patients with advanced esophageal cancer at PD-L1 combined positive score≥10. J Comp Eff Res. 2022;11(15):1095–103.

Article  CAS  PubMed  Google Scholar 

Lang W, Wei J, Jiang Q, et al. Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma. Int J Clin Pharm. 2023. https://doi.org/10.1007/s11096-023-01662-1.

Article  PubMed  Google Scholar 

Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Mak. 2012;32(5):722–32.

Article  Google Scholar 

Shi F, He Z, Su H, et al. Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China. Front Pharmacol. 2022;13:961347.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhan M, Xu T, Zheng H, et al. Cost-effectiveness analysis of pembrolizumab in patients with advanced esophageal cancer based on the KEYNOTE-181 study. Front Public Health. 2022;10:790225.

Article  PubMed  PubMed Central  Google Scholar 

Liu S, Dou L, Li S. Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China. Front Pharmacol. 2023;14:1055727.

Article  PubMed  PubMed Central  Google Scholar